JP2007509607A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509607A5
JP2007509607A5 JP2006530599A JP2006530599A JP2007509607A5 JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5 JP 2006530599 A JP2006530599 A JP 2006530599A JP 2006530599 A JP2006530599 A JP 2006530599A JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid construct
antigen
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006530599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509607A (ja
JP4814099B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2004/004279 external-priority patent/WO2005035771A2/en
Publication of JP2007509607A publication Critical patent/JP2007509607A/ja
Publication of JP2007509607A5 publication Critical patent/JP2007509607A5/ja
Application granted granted Critical
Publication of JP4814099B2 publication Critical patent/JP4814099B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006530599A 2003-10-10 2004-10-11 核酸構築物 Expired - Fee Related JP4814099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50993603P 2003-10-10 2003-10-10
US60/509,936 2003-10-10
PCT/GB2004/004279 WO2005035771A2 (en) 2003-10-10 2004-10-11 Nucleic acid constructs

Publications (3)

Publication Number Publication Date
JP2007509607A JP2007509607A (ja) 2007-04-19
JP2007509607A5 true JP2007509607A5 (enExample) 2007-12-06
JP4814099B2 JP4814099B2 (ja) 2011-11-09

Family

ID=34435038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530599A Expired - Fee Related JP4814099B2 (ja) 2003-10-10 2004-10-11 核酸構築物

Country Status (21)

Country Link
US (1) US8663657B2 (enExample)
EP (1) EP1685251B1 (enExample)
JP (1) JP4814099B2 (enExample)
KR (2) KR101234981B1 (enExample)
CN (1) CN1890375B (enExample)
AU (1) AU2004279991B2 (enExample)
BR (1) BRPI0415204A (enExample)
CA (1) CA2542288A1 (enExample)
DK (1) DK1685251T3 (enExample)
EA (1) EA010056B1 (enExample)
ES (1) ES2457022T3 (enExample)
IL (1) IL174848A (enExample)
MX (1) MXPA06003978A (enExample)
NO (1) NO20062080L (enExample)
NZ (1) NZ546554A (enExample)
PL (1) PL1685251T3 (enExample)
PT (1) PT1685251E (enExample)
SG (1) SG147430A1 (enExample)
SI (1) SI1685251T1 (enExample)
WO (1) WO2005035771A2 (enExample)
ZA (1) ZA200603685B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
CA2624615A1 (en) * 2005-10-05 2007-04-19 Bayhill Therapeutics, Inc. Compositions and methods for treatment of autoimmune disease
CA2724908C (en) 2008-07-23 2017-03-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hgh polyadenylation signal
AU2010326132B9 (en) * 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
CN101993878B (zh) * 2010-10-14 2012-04-18 南京农业大学 一种rRNA嵌合启动子及含有该嵌合启动子的表达载体
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
EP4043025A1 (en) 2011-06-08 2022-08-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
ES2660129T3 (es) 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
US9890391B2 (en) * 2012-03-27 2018-02-13 Curevac Ag RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
CA2859452C (en) 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
HUE026516T2 (en) 2012-09-24 2016-06-28 Lonza Biologics Plc Expression vectors containing chimeric cytomegalovirus promoter and enhancer sequences
WO2014102101A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP2938728B1 (en) * 2012-12-31 2020-12-09 Boehringer Ingelheim International GmbH Artificial introns
EP2938725B1 (en) 2012-12-31 2017-08-23 Boehringer Ingelheim International GmbH Heterologous intron within an immunoglobulin domain
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
TR201901310T4 (tr) 2013-03-14 2019-02-21 Translate Bio Inc Mesajcı RNA'nın saflaştırılması yöntemleri.
LT2968586T (lt) 2013-03-14 2018-11-26 Translate Bio, Inc. Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのｍＲＮＡ療法
JP6608815B2 (ja) 2013-10-22 2019-11-20 トランスレイト バイオ， インコーポレイテッド アルギニノコハク酸合成酵素欠損症のｍＲＮＡ治療
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
SG10201903381TA (en) * 2013-12-30 2019-05-30 Curevac Ag Artificial nucleic acid molecules
CN103901209B (zh) * 2014-02-18 2016-05-25 王明丽 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒
CN106164248B (zh) 2014-04-25 2019-10-15 川斯勒佰尔公司 信使rna的纯化方法
US10563222B2 (en) * 2014-06-18 2020-02-18 Agency For Science, Technology And Research Promoters for high level expression
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2019060649A1 (en) * 2017-09-22 2019-03-28 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
US5100792A (en) * 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
DE69529495T2 (de) * 1994-01-21 2003-06-12 Powderject Vaccines, Inc. Gasbetätigtes element zum austragen von genmaterial
WO1995020660A2 (en) 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
AU716676B2 (en) * 1995-05-24 2000-03-02 Hawaii Biotech, Inc. Subunit vaccine against flavivirus infection
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
GB9715064D0 (en) 1997-07-17 1997-09-24 Ppl Therapeutics Scotland Ltd Protein expression
US20020106635A1 (en) 1998-05-27 2002-08-08 Bruce Freimark Cytokine resistant cytomegalovirus promoter mutants and related products and methods
DE69930294T2 (de) 1998-10-19 2006-11-02 Powderject Vaccines, Inc., Madison Minimale promotoren und ihre verwendung
WO2001058483A2 (en) 2000-02-08 2001-08-16 The University Of Virginia Patent Foundation METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US20030124523A1 (en) * 2000-06-22 2003-07-03 Asselbergs Fredericus Alphonsus Maria Organic compounds
EP1373524B1 (en) * 2000-10-13 2006-04-12 Chiron Corporation Cytomegalovirus intron a fragments
MXPA03004638A (es) 2000-11-27 2004-04-20 Powderject Vaccines Inc Adyuvantes de acido nucleico.
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2002094313A2 (en) 2001-05-18 2002-11-28 Powderject Vaccines, Inc. Vaccine composition
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
NZ547042A (en) 2003-10-10 2010-05-28 Powderject Vaccines Inc Method for eliciting a T-cell response
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs

Similar Documents

Publication Publication Date Title
JP2007509607A5 (enExample)
JP6903120B2 (ja) アルファウイルスワクチン接種のための組成物及び方法
JP2025084808A (ja) エプスタイン－バーウイルスワクチン
CN104884082B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
Qi et al. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection
CN116390752A (zh) 自扩增性sars-cov-2rna疫苗
US6831169B2 (en) Hepatitis C virus vaccine
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
WO2000011140A1 (en) Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
CA2447450A1 (en) Corona-virus-like particles comprising functionally deleted genomes
JP2021509107A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用
JP2008528020A (ja) 核酸構築物
CN101573449A (zh) 用于治疗慢性乙型肝炎的dna疫苗及其制备方法
CN120459288A (zh) 融合蛋白疫苗平台的构建与应用
US20240335531A1 (en) Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
CN114729010B (zh) 乙型肝炎病毒疫苗
CN112641937B (zh) 一种重组腺病毒在制备预防病毒的药物中的用途
US20220249647A1 (en) Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020254876A1 (en) Virus-like particle delivery of hepatitis b virus (hbv) vaccines
CN118791633A (zh) 一种预防病毒性心肌炎的细菌样颗粒疫苗及其制备方法和应用
CN117018175A (zh) 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用
CN103239717B (zh) 治疗慢性乙型肝炎的复制子dna疫苗
JP2023546603A (ja) 外来抗原をコードする遺伝物質を含む、ターゲット組織の大きさまたは体積の縮小用のワクチン組成物またはキット
WO2004072274A1 (en) Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
KR102766523B1 (ko) 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트